Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.48 USD | +0.49% | -1.83% | -10.38% |
May. 10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.38% | 6.22B | |
+4.73% | 109B | |
+11.58% | 105B | |
+0.35% | 22.25B | |
-11.84% | 22.09B | |
-7.82% | 18.68B | |
-38.36% | 17.58B | |
-9.42% | 16.85B | |
+4.96% | 13.76B | |
+37.12% | 12.46B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Insider Sold Shares Worth $575,250, According to a Recent SEC Filing